

# 1 Alzheimer's Disease biological PET staging using plasma 2 p217+tau 3

4 Azadeh Feizpour<sup>1,2</sup>, Vincent Doré<sup>2,3</sup>, Natasha Krishnadas<sup>1,2</sup>, Pierrick Bourgeat<sup>4</sup>, James D.  
5 Doecke<sup>4,5</sup>, Ziad S. Saad<sup>6</sup>, Gallen Triana-Baltzer<sup>6</sup>, Simon M. Laws<sup>5,7,8</sup>, Rosita Shishegar<sup>3,9</sup>, Kun  
6 Huang<sup>2</sup>, Christopher Fowler<sup>1</sup>, Larry Ward<sup>1</sup>, Colin L. Masters<sup>1</sup>, Jurgen Fripp<sup>4</sup>, Hartmuth C.  
7 Kolb<sup>6</sup>, Victor L. Villemagne<sup>2,10</sup>, Christopher C. Rowe<sup>1,2,11,\*</sup>  
8  
9

10 *1 The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville,*  
11 *Victoria, Australia;*

12 *2 Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia;*

13 *3 The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia;*

14 *4 The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia;*

15 *5 Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia;*

16 *6 Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA;*

17 *7 Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western*  
18 *Australia, Australia;*

19 *8 Curtin Medical School, Curtin University, Bentley, Western Australia, Australia;*

20 *9 School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash*  
21 *University, Melbourne, Victoria, Australia;*

22 *10 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;*

23 *11 Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne,*  
24 *Victoria, Australia.*

25  
26  
27 \*Address correspondence to: Professor Christopher C Rowe, Department of Molecular Imaging &  
28 Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC. 3084, Australia. Telephone: +61-3-9496  
29 3321. Fax +61-3-9458 5023.

30 *Email: [christopher.rowe@austin.org.au](mailto:christopher.rowe@austin.org.au)*

## 31 Abstract

32 **Background:** Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying  
33 Alzheimer's Disease (AD) neuropathology. However, questions remain regarding their  
34 capacity to inform AD biological PET stages at group level and maintain the same precision  
35 at individual patient level.

36 **Method:** Participants included 248 cognitively unimpaired (CU) and 227 cognitively  
37 impaired (CI) individuals, with Janssen plasma p217+tau Simoa® assay, <sup>18</sup>F-NAV4694 Aβ  
38 PET (A) and <sup>18</sup>F-MK6240 tau PET (T) data. Biological PET stages were defined based on the  
39 draft NIA-AA Revised Criteria (July 2023): Initial (A+T-), Early (A+T<sub>MTL</sub>+), Intermediate  
40 (A+T<sub>MOD</sub>+), and Advanced (A+T<sub>HIGH</sub>+). We used thresholds for A+ of 25 Centiloid and for  
41 T<sub>HIGH</sub> of 80 Centaur (2.68 SUVR<sub>temporo-parietal</sub>). Adding an A-T- stage for comparison, we  
42 assessed the performance of p217+tau in discriminating between these stages at the group  
43 level using Receiver Operating Characteristic (ROC) analysis and at the individual level  
44 using logistic regression.

45 **Results:** Plasma p217+tau concentrations increased across the stages, with significant  
46 differences between them, except for the Initial and Early stages. Screening for Advanced (*vs.*  
47 lower stages), combined Intermediate/Advanced (*vs.* lower stages), or all stages (*vs.* A-T-),  
48 p217+tau showed good group-level discriminations (AUC 0.91, 0.92 and 0.92; CI only: AUC  
49 0.83, 0.89, 0.93, respectively). At the individual level, the likelihood of PET stage *vs.*  
50 p217+tau level showed good discrimination of A-T- *vs.* any A+ stage and of combined  
51 Intermediate/Advanced disease stage *vs.* lower stages in the CI.

52 **Conclusion:** In addition to accurately screening for A+ individuals, plasma p217+tau shows  
53 promise for separating persons with either Intermediate or Advanced stage AD from those at  
54 a lower stage, providing prognostic information and informing better selection for trials and  
55 disease modifying therapies.

## 56 Introduction

57 The *in vivo* staging of Alzheimer's disease (AD) has become increasingly important,  
58 particularly in light of the recent breakthroughs in disease-modifying therapies for AD <sup>1</sup>.  
59 Positron Emission Tomography (PET) imaging allows *in vivo* staging however, the cost and  
60 limited scalability underscores the need to assess plasma biomarkers for this purpose. Among  
61 a range of plasma biomarkers, measures of phosphorylated tau (p-tau) at amino acid 217 (p-  
62 tau217) have demonstrated significant potential, rivalling the gold-standards of amyloid-beta  
63 (Ab) PET and cerebrospinal fluid (CSF) <sup>2</sup>.

64 The plasma "p217+tau" assay is a high sensitivity Simoa assay using a capture antibody  
65 (pT3), raised against tau paired helical filaments (PHF), that binds to phosphorylation at  
66 aa217 (p217) with enhanced binding when other nearby phosphorylated sites are present,  
67 predominantly at aa212. It has shown a similar performance to p-tau217 in detecting A $\beta$   
68 status in CSF, distinguishing clinical diagnostic groups and predicting progression from Mild  
69 Cognitive Impairment (MCI) to AD <sup>3</sup>. A comparison of its performance to recent-generation  
70 PET tracers has demonstrated similarly good diagnostic accuracy <sup>4</sup>. Furthermore, we have  
71 previously shown that p217+tau predicted cognitive decline and if used as a pre-screening  
72 tool in pre-clinical AD trials or screening tool in MCI/AD trials, substantial cost reduction  
73 could be achieved <sup>5</sup>. While accumulating evidence underscores the excellent diagnostic,  
74 prognostic, and clinical trial utility of plasma p-tau biomarkers, their performance in disease  
75 staging is at present understudied. Disease staging needs to be assessed at both group level  
76 and individual level. Group-level analysis establishes receiver operating characteristic  
77 (ROC)-based thresholds (such as 90% sensitivity or 90% positive predictive value (PPV)  
78 thresholds) that have proven useful in enriching clinical trial populations. Individual-level  
79 analysis provides the foundation for development of risk assessment models aimed at the  
80 identification of individuals at elevated risk for specific stages of AD to tailor their prognosis  
81 and treatment.

82 A recent report by Jack *et al.* <sup>6</sup> examined whether p-tau217 could discriminate between AD  
83 disease stages. They defined four tau PET topographic stages using Braak-like PET staging  
84 schemes <sup>7,8</sup> and group-level results indicated a good discrimination between Braak 0 and  
85 Braak 1-6 stages in the cognitively unimpaired participants.

86 In the present study, we were interested in both individual-level and group-level  
87 discrimination of disease stages. Therefore, we employed the biological PET staging of AD,  
88 recently proposed by draft NIA-AA Revised Diagnosis and Staging Criteria (2023) <sup>9</sup> and

89 aimed to assess the ability of plasma p217+tau to discriminate individuals that fall within  
90 these stages.

## 91 Methods

### 92 Participants

93 From AIBL and ADNeT cohorts, 475 participants with  $^{18}\text{F}$ -MK6240 tau PET,  $^{18}\text{F}$ -NAV4694  
94  $\text{A}\beta$  PET and plasma p217+tau were selected. Details of cohort recruitment and evaluation are  
95 described elsewhere <sup>10</sup>. Briefly, all participants were clinically classified as cognitively  
96 unimpaired (CU), or participants with mild cognitive impairment (MCI), Alzheimer's disease  
97 (AD) dementia or non-AD dementia, by a multi-disciplinary panel blind to PET imaging and  
98 blood assays results. The MCI and dementia groups were combined into a cognitively  
99 impaired (CI) group for some analyses. A diagnosis of CU required performance within 1.5  
100 standard deviations (SD) of the published norms for their age group on selected  
101 neuropsychological assessments. A diagnosis of MCI or AD dementia followed the  
102 internationally agreed clinical criteria <sup>11, 12</sup>. Approval was obtained from institutional ethics  
103 review committees for the AIBL and ADNeT studies and written informed consent was  
104 obtained from all participants.

### 105 PET Image Acquisition and Analysis

106  $\text{A}\beta$  PET imaging involved a 20-minute acquisition, performed 50 minutes after injection of  
107 200 MBq of  $^{18}\text{F}$ -NAV4694 intravenously. Tau PET imaging was conducted on a separate  
108 day, with a 20-minute acquisition, performed 90 minutes after intravenous administration of  
109 185 MBq of  $^{18}\text{F}$ -MK6240. For  $\text{A}\beta$  PET scans, spatial normalization was achieved using  
110 CapAIBL <sup>13</sup> and the results were standardised using the Centiloid (CL) scale <sup>14, 15</sup>. For tau  
111 PET scans, spatial normalization was performed using the MR-less CapAIBL PCA-based  
112 method <sup>16</sup>. Tau PET scans were scaled using the cerebellar cortex as the reference region.  $^{18}\text{F}$ -  
113 MK6240 standardized uptake value ratio (SUVR) was estimated for three in-house composite  
114 regions of interest (ROI): 1) mesial temporal (Me) ROI, comprising entorhinal cortex,  
115 amygdala, hippocampus, and parahippocampus, 2) temporoparietal (Te) ROI, consisting of  
116 inferior temporal, fusiform, supramarginal and angular gyri, posterior cingulate/ precuneus,  
117 superior and inferior parietal, and lateral occipital cortex and 3) rest of neocortex (R)  
118 including dorsolateral and ventrolateral prefrontal, orbitofrontal, gyrus rectus, superior and  
119 middle temporal, and anterior cingulate <sup>17</sup>. A CL threshold of 25 was selected to discriminate  
120  $\text{A}\beta$  positive (A+) vs.  $\text{A}\beta$  negative (A-) PET scans. Previously reported thresholds based on  
121 the 95<sup>th</sup> percentile of A- CU were used to discriminate tau positive (T+) from tau negative (T-  
122 ) PET scans—1.18 SUVR for Me, 1.24 SUVR for Te and 1.08 SUVR for R <sup>18</sup>. For tau PET

123 uptake in the moderate SUVR range in the Te ROI, we considered values between 1.24 and  
124 2.68. The upper threshold of 2.68 Te SUVR corresponds to 80 CenTauR<sup>19,20</sup>. We considered  
125 80 CenTauR as a cut-off point between low/medium (or intermediate) and high tau burden, as  
126 we calculated that this approximates the threshold used for tau PET staging (intermediate vs.  
127 high) in the Trailblazer-Alz 2 randomized clinical trial<sup>1</sup>.

## 128 Plasma p217+tau Assay

129 Fasting blood was collected 2.4 ± 10.4 months from the time of Aβ PET scan and 0.1 ± 4.2  
130 months from the tau PET scan. Plasma from K2-EDTA tubes (7.5 mL S-monovette  
131 01.1605.008, Sarstedt), containing prostaglandin E1 (33 ng/mL of whole blood, Sapphire  
132 Biosciences), was centrifuged at room temperature for 10 mins at 200g to collect platelet-rich  
133 plasma. Then, to provide plasma that was snap frozen within 2 hr of collection, it was  
134 centrifuged at 800g for 10 mins, following which it was stored in vapour phase liquid  
135 nitrogen prior to shipping on dry ice from Australia to Janssen R&D, La Jolla, CA, USA. The  
136 plasma p217+tau assay was completed on a Single Molecule Array (Simoa®) HD-X  
137 platform, blinded to all subject data. The technique has been previously described by Triana-  
138 Baltzer *et al.*<sup>21</sup>. Plasma p217+tau assay results from two laboratories, Janssen R&D (cohort  
139 1; n=397) and Quanterix Corp, MA, USA (cohort 2; n=317), were combined. This study  
140 included all participants from cohort 2, and those unique to cohort 1 who were not already  
141 part of cohort 2 (final n=506). Assay scales measured from both laboratories were  
142 comparable.

## 143 Implementation of 2023 Proposed NIA-AA Staging of AD with PET:

144 In the draft NIA-AA Revised Diagnostic and Staging Criteria (2023)<sup>9</sup>, the following  
145 biological PET staging scheme is proposed: 1. Initial stage: proposed as abnormal Aβ with no  
146 tau uptake (A+T-), 2. Early stage: as abnormal Aβ with tau uptake limited to medial temporal  
147 region (A+T<sub>MTL</sub>+), 3. Intermediate stage: as abnormal Aβ with moderate tau uptake in a  
148 neocortical ROI (A+T<sub>MOD</sub>+), and 4. Advanced stage: as abnormal Aβ with high tau uptake in  
149 the same neocortical region (A+T<sub>HIGH</sub>+). For stages 3 and 4, we considered Te as our  
150 neocortical ROI. Table 1 displays our selected CL and SUVR cut-offs and ranges for defining  
151 the aforementioned stages:

152

153

154 Table 1. Biological PET staging

PET stages	Centiloid	Tau (SUVR)		
		Me	Te	R
Initial: A+T-	≥ 25	< 1.18	< 1.24	< 1.08
Early: A+T <sub>MTL</sub> +	≥ 25	≥ 1.18	< 1.24	< 1.08
Intermediate: A+T <sub>MOD</sub> +	≥ 25	< or ≥ 1.18	Between 1.24 & 2.68	_____
Advanced: A+T <sub>HIGH</sub> +	≥ 25	< or ≥ 1.18	≥ 2.68	_____

155 In addition, we considered an A-T- group, to allow comparison:

A-T-	< 25	< 1.18	< 1.24	< 1.08
------	------	--------	--------	--------

156 *SUVR* standardized uptake value ratio; *Me* mesial temporal ROI; *Te* temporoparietal ROI;  
157 *R* rest of neocortex ROI.

158 Of the 506 participants with available plasma p217+tau assay results, 31 who were A- but T+  
159 in one or all three ROIs did not fit within any of the above AT categories and were excluded  
160 from subsequent analyses. Among these, 11 had mildly elevated MTL binding and were  
161 postulated to have primary age related tauopathy (PART) but 9 were positive on  
162 quantification in MTL and temporo-parietal. This proportion of the total study sample of ~2%  
163 as having clearly positive neocortical tau PET but negative amyloid PET is consistent with  
164 our previous report <sup>22</sup> (see Supplementary Table 1 for demographic characteristics of the  
165 excluded participants).

## 166 Statistical Methods

167 All statistical analyses were completed using Python version 3.9.13, unless otherwise  
168 specified. Demographic differences between groups were assessed using one-way ANOVA  
169 for continuous data and Pearson's  $\chi^2$  test of independence for categorical variables (gender,  
170 Apolipoprotein E (*APOE*)  $\epsilon 4$  status, clinical diagnosis). Pairwise comparisons for continuous  
171 data were performed using Tukey Honest Significant Difference (HSD) test while categorical  
172 variables were analysed with Pearson's  $\chi^2$  test. Bonferroni correction was applied to all  
173 multiple pairwise comparisons. To investigate the magnitude of differences in plasma  
174 p217+tau concentration across the PET stages, effect sizes were estimated using Cohen's *d*.  
175 ROC analysis was used to assess group-level discriminatory capability. The area under the  
176 ROC curve (AUC) from each comparison was used to assess the performance of p217+tau  
177 alone or in combination with other predictors (age, gender and *APOE*  $\epsilon 4$  status) in  
178 discriminating different PET stages. The AUCs were compared using DeLong test (R version  
179 4.2.3). Specificity, sensitivity, PPV and negative predictive value (NPV) were reported with  
180 bootstrapped 95% confidence intervals (shown in square brackets). PPV and NPV were not

181 adjusted for disease prevalence. Optimal p217+tau thresholds for discriminating between the  
182 biological PET stages were derived using Youden's Index.

183 Given that there were only nine participants with p217+tau values above 500 fg/ml, with a  
184 range from 507 to 902 fg/ml (6 of whom were A+T<sub>HIGH</sub>+ and 3 were A+T<sub>MOD</sub>+) and  
185 considering the limited statistical power to estimate the line of best fit, we restricted our  
186 regression analyses to plasma p217+tau concentrations between 0 and 500 fg/ml in the  
187 subsequent sections. To evaluate the probability of a participant belonging to a distinct PET  
188 stage (individual patient-level staging), we employed two methods. In the first approach, we  
189 computed probability scores by applying a binary logistic regression model. In this model, we  
190 used plasma p217+tau as the predictor (independent variable) and grouped PET stages as the  
191 outcome (dependent variable), where the stages were categorized into binary groups of 0 and  
192 1. Then, we compared the results of the logistic regression to the second approach, a sliding  
193 window method. Here, we calculated PET stage probabilities within sequential bands of  
194 plasma p217+tau concentrations, with each band spanning 80 fg/ml. We selected an 80 fg/ml  
195 band width as a balance between achieving overly smoothed curves and avoiding excessive  
196 noise. The calculated probability for each band was centred at the midpoint of the p217+tau  
197 concentration range. The probability estimates from both methods were plotted against  
198 p217+tau concentrations and compared across the biological PET stages.



## 199 Results

### 200 Participant demographics

201 Demographic characteristics of the participants are presented in Table 2. Participants  
 202 included 248 CU, 144 with MCI and 83 with dementia (total n = 475). Among these, 192  
 203 were categorized as A-T-, 80 as A+T-, 31 as A+T<sub>MTL</sub>+, 128 as A+T<sub>MOD</sub>+, and 44 as  
 204 A+T<sub>HIGH</sub>+. The A+T<sub>HIGH</sub>+ group had a younger average age and lower level of education  
 205 compared to the other groups. No significant gender differences were observed among the  
 206 groups. Relative to A-T-, all other groups displayed higher rates of *APOE* ε4 carriership and  
 207 greater prevalence of MCI or dementia diagnosis. These groups also exhibited higher  
 208 Centiloid values and plasma p217+tau concentrations. The A+T<sub>MOD</sub>+ and A+T<sub>HIGH</sub>+ had  
 209 lower MMSE scores, and A+T-, A+T<sub>MOD</sub>+, and A+T<sub>HIGH</sub>+ had higher CDR-SoB scores. For  
 210 a breakdown of participant demographics by clinical diagnosis, see Supplementary Table 2.


211 Table 2. Demographic characteristics

	A-T-	A+T-	A+T <sub>MTL</sub> +	A+T <sub>MOD</sub> +	A+T <sub>HIGH</sub> +	<i>p</i>
n	192	80	31	128	44	—
Age (years)	74.1 ± 6.2	76.0 ± 7.2	75.2 ± 8.4	75.5 ± 7.1	68.3 ± 7.8 ***	<0.001
Education (years)	13.7 ± 3.1	12.9 ± 3.4	12.9 ± 2.7	12.6 ± 2.8	12.1 ± 2.8 *	0.013
Gender, F (%)	50.00%	42.50%	45.20%	53.90%	50.00%	0.589
<i>APOE</i> ε4 (%)	21.10%	50.60% ***	74.20% ***	68.50% ***	62.80% ***	<0.001
MMSE	28.4 ± 1.7	27.4 ± 2.3	26.8 ± 2.8	25.0 ± 4.1 ***	21.7 ± 5.9 ***	<0.001
CDR_SoB	0.4 ± 1.1	1.5 ± 2.7 **	1.6 ± 1.8	2.6 ± 2.9 ***	4.8 ± 3.3 ***	<0.001
Centiloid (CL)	0.8 ± 7.4	75.6 ± 39.1***	91.6 ± 39.0***	119.6 ± 41.0 ***	122.2 ± 32.2***	<0.001
Tau PET, Me (SUVR)	0.9 ± 0.1	0.9 ± 0.1	1.4 ± 0.2 ***	1.8 ± 0.4 ***	2.3 ± 0.6 ***	<0.001
Tau PET, Te (SUVR)	1.0 ± 0.1	1.0 ± 0.1	1.1 ± 0.1	1.8 ± 0.4 ***	3.6 ± 0.9 ***	<0.001
Plasma p217+tau (fg/ml)	69.5 ± 36.7	127.0 ± 54.1 ***	147.8 ± 51.8 ***	227.9 ± 98.2 ***	363.2 ± 163.3 ***	<0.001
MCI or Dementia (%)	18.80%	40.00% ***	54.80% ***	78.10% ***	95.50% ***	<0.001

212 Values presented as mean ± SD for all variables except n, Gender, Apolipoprotein E  
 213 (*APOE*) ε4 and MCI or Dementia (%). *SD* Standard deviation; *MMSE* mini-mental state  
 214 examination; *CDR-SB* clinical dementia rating sum of boxes; *MCI* Mild Cognitive  
 215 Impairment. \* *p*<0.05, \*\* *p*<0.01, \*\*\* *p*<0.001 for comparison to A-T- (corrected for  
 216 multiple comparisons).

## 217 Plasma p217+tau concentration by PET stages

218 The median concentration of plasma p217+tau exhibited a clear incremental trend across the  
219 stages, with values of 63.5 fg/ml in the A-T-, 118.7 fg/ml in A+T-, 140.7 fg/ml in A+T<sub>MTL</sub>+,  
220 211.0 fg/ml in A+T<sub>MOD</sub>+ and 336.7 fg/ml in A+T<sub>HIGH</sub>+ (Figure 1). A pairwise comparison—  
221 corrected for multiple comparisons—revealed significant differences in mean plasma  
222 p217+tau concentration between all stages, except for the comparison between A+T- and  
223 A+T<sub>MTL</sub>+. Henceforth, in all subsequent analyses, these two stages were consolidated into a  
224 unified stage referred to as Initial/Early (A+T<sub>None/MTL</sub>). For detailed information on Cohen's *d*  
225 effect sizes and *p*-values for comparison between the stages, see Supplementary Table 3.



226  
227 Figure 1. Plasma p217+tau levels in the different PET stages. The error bars in the  
228 boxplots represent 1.5 times the interquartile range (IQR) above and below the upper (75<sup>th</sup>  
229 percentile) and lower (25<sup>th</sup> percentile) quartiles. Plasma p217+tau concentrations exhibited  
230 a clear incremental trend across these stages, with significant differences between all,  
231 except for the Initial and Early stages. A-T- amyloid negative and tau negative; A+T-  
232 amyloid positive and tau negative; A+T<sub>MTL</sub>+ amyloid positive with tau uptake limited to  
233 medial temporal region; A+T<sub>MOD</sub>+ amyloid positive with moderate tau uptake in temporo-  
234 parietal region; A+T<sub>HIGH</sub>+ amyloid positive with high tau uptake in temporo-parietal  
235 region. \*\*\* *p*<0.001 (corrected for multiple comparisons); *ns* non-significant.

## 236 Group-level approach for disease staging

### 237 Discrimination between A-T- and A+ stages

238 In a clinical trial investigating the effect of a disease-modifying treatment on all biological  
239 PET stages of AD, discriminating between those stages and A-T- would be important.

240 Our findings showed that when CU and CI participants were combined, plasma p217+tau  
241 alone discriminated between A-T- and all stages combined of A+, with an AUC of 0.92


242 (Figure 2A), significantly better than the discrimination by the base model which included  
243 age, gender and *APOE*  $\epsilon$ 4 status (AUC: 0.75,  $p < 0.001$ ). The Youden index provided a  
244 threshold concentration of 99.4 fg/ml [89.7 - 102.4 fg/ml], which yielded sensitivity of 0.87  
245 [0.83 - 0.91], specificity of 0.84 [0.78 - 0.88], PPV of 0.89 [0.85 - 0.92] and NPV of 0.81  
246 [0.77 - 0.87] (Supplementary Table 4). Adding age or gender separately did not improve the  
247 AUC of the model with p217+tau while *APOE*  $\epsilon$ 4 status improved the model slightly (AUC:  
248 0.94,  $p < 0.05$ ). The full model including p217+tau, age, gender and *APOE*  $\epsilon$ 4 status yielded  
249 the highest AUC (0.94,  $p < 0.01$  compared to model with p217+tau only).  
250 Among CI only participants, plasma p217+tau discriminated between A-T- and A+  
251 individuals with an AUC of 0.93 (Figure 2D), significantly better than the discrimination by  
252 the base model (AUC: 0.82,  $p < 0.05$ ). Youden threshold of 126.7 fg/ml [94.8 - 149.9 fg/ml]  
253 gave a sensitivity of 0.83 [0.69 - 0.95], specificity of 0.86 [0.79 - 1.0], PPV of 0.97 [0.96 -  
254 1.0], and NPV of 0.48 [0.34 - 0.74] (Supplementary Table 5). Adding age, gender or *APOE*  
255  $\epsilon$ 4 status separately did not improve the model with p217+tau. However, adding all predictors  
256 together (full model) had the highest AUC (0.96,  $p < 0.05$  compared to model with p217+tau  
257 only).

#### 258 *Discrimination between combined A-T-/A+T<sub>None/MTL</sub> and combined A+T<sub>MOD</sub>+/A+T<sub>HIGH</sub>+*

259 In a clinical trial assessing the impact of a disease-modifying treatment on individuals with  
260 A $\beta$  and intermediate or high neocortical tau pathology, screening for these individuals vs. A-  
261 T-/A+T<sub>None/MTL</sub> individuals becomes a crucial consideration.  
262 Among the CU & CI combined, for discriminating these two groups, using p217+tau alone,  
263 the AUC was 0.92 (Figure 2B), performing significantly better than the base model (AUC:  
264 0.69,  $p < 0.001$ ). Youden index gave a threshold of 168.0 fg/ml [131.8 - 177.4 fg/ml] which  
265 yielded a sensitivity of 0.77 [0.73 - 0.90], specificity of 0.91 [0.80 - 0.95], PPV of 0.84 [0.71  
266 - 0.89], and NPV of 0.88 [0.85 - 0.93] (Supplementary Table 4). Adding age, gender or  
267 *APOE*  $\epsilon$ 4 status separately or together did not improve the AUC of the model with p217+tau.  
268 Among the CI only, the AUC was 0.89 (Figure 2E), significantly better than the  
269 discrimination by the base model (AUC: 0.65,  $p < 0.001$ ), Youden threshold 177.4 fg/ml  
270 [168.0 - 179.4 fg/ml], sensitivity 0.78 [0.74 - 0.86], specificity 0.92 [0.85 - 0.96], PPV 0.94  
271 [0.89 - 0.97], NPV 0.72 [0.66 - 0.81] (Supplementary Table 5). Adding age, gender or *APOE*  
272  $\epsilon$ 4 status separately or together did not improve the model with p217+tau.

273 *Discrimination between combined A-T-/A+T<sub>None/MTL</sub>/A+T<sub>MOD+</sub> and A+T<sub>HIGH+</sub>*

274 In a therapeutic trial evaluating the effect of an intervention in the Advanced (high  
275 neocortical tau) group only, or wishing to exclude those with Advanced tau, discrimination  
276 between A-T-/A+T<sub>None/MTL</sub>/A+T<sub>MOD+</sub> and A+T<sub>HIGH+</sub> will be crucial.  
277 Among the CU & CI combined, the use of plasma p217+tau alone for discriminating between  
278 these two groups gave an AUC of 0.91 (Figure 2C), significantly better than the  
279 discriminatory performance of the base model (AUC: 0.75,  $p < 0.01$ ). Youden index yielded a  
280 threshold of 205.4 fg/ml [173.2 - 257.9 fg/ml] with a sensitivity of 0.89 [0.79 - 0.97],  
281 specificity of 0.82 [0.75 - 0.90], PPV of 0.33 [0.25 - 0.47], NPV of 0.99 [0.98 - 1.0]  
282 (Supplementary Table 4). Adding age, gender or *APOE*  $\epsilon 4$  status separately or together did  
283 not improve the model with p217+tau.  
284 When only CI participants were included, plasma p217+tau alone discriminated between  
285 these two groups with an AUC of 0.84 (Figure 2F) and this AUC did not significantly differ  
286 from any of the other models. Youden index provided a threshold of 230.3 fg/ml [205.4 -  
287 299.5 fg/ml] giving sensitivity of 0.84 [0.69 - 0.95], and specificity 0.71 [0.64 - 0.88]  
288 (Supplementary Table 5). With PPV of 0.39 [0.31 - 0.58] and NPV of 0.95 [0.92 - 0.98],  
289 p217+tau effectively excluded Advanced stage AD when less than the Youden threshold but  
290 did not accurately predict Advanced stage when above, predominantly due to the presence of  
291 many Intermediate stage AD participants with p217+tau above the threshold.  
292 For a pairwise comparison of each two biological PET stages, see Supplementary Table 6.



293

294 Figure 2. ROC analysis for group-level PET staging, CU and CI combined (Top panel), and  
 295 CI only (Bottom panel). Base model includes age, gender, and Apolipoprotein E (*APOE*)  
 296  $\epsilon 4$  status. Full model includes p217+tau, age, gender, and *APOE*  $\epsilon 4$  status. *pT217* plasma  
 297 p217+tau; *AUC* area under the receiver operating characteristic curve. *A-T-* amyloid  
 298 negative and tau negative; *A+T<sub>None/MTL</sub>* amyloid positive and tau negative or amyloid  
 299 positive with tau uptake limited to medial temporal region; *A+T<sub>MOD+</sub>* amyloid positive  
 300 with moderate tau uptake in temporo-parietal region; *A+T<sub>HIGH+</sub>* amyloid positive with high  
 301 tau uptake in temporo-parietal region. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  for comparison of  
 302 the model with p217+tau only, to the base model (corrected for multiple comparisons).  
 303 # $p < 0.05$ , ## $p < 0.01$ , for comparison of models with additional predictors to the model with  
 304 p217+tau only (after correction for multiple comparisons).

### 305 *Discrimination between disease stages of enrolled participants*

306 In the preceding sections, we demonstrated that employing a Youden threshold of 177.4  
 307 fg/ml allowed screening for CI participants who were either *A+T<sub>MOD+</sub>* or *A+T<sub>HIGH+</sub>*, with a  
 308 PPV of 0.94. In some therapeutic trials, it might be essential to stage enrolled participants for  
 309 analytical purposes. For instance, one may wish to assess the impact of an intervention only  
 310 in participants with high neocortical tau (*A+T<sub>HIGH+</sub>*). This led us to enquire whether, in the


311 absence of A $\beta$  and tau PET imaging, p217+tau could discriminate between A+T<sub>HIGH+</sub> and  
312 those at lower stages in participants with p217+tau values above 177.4 fg/ml (pT<sub>177.4+</sub>).  
313 Among the pT<sub>177.4+</sub> participants, for discriminating between the A+T<sub>HIGH+</sub> and the lower  
314 stages, the AUC was 0.76 [0.68 - 0.83], Youden index threshold 299.5 fg/ml [257.9 - 402.9],  
315 sensitivity 0.71 [0.47 - 0.91], specificity 0.70 [0.52 - 0.95], PPV 0.52 [0.41 - 0.79], NPV 0.84  
316 [0.76 - 0.93]. This indicates that this threshold could be potentially used to rule out  
317 A+T<sub>HIGH+</sub>, among the pT<sub>177.4+</sub> participants.

### 318 Individual-level approach for disease staging

319 We also performed logistic regressions to ascertain whether an individual's plasma p217+tau  
320 level can inform their classification into A-T-, Initial-Early (A+T<sub>None/MTL</sub>), Intermediate  
321 (A+T<sub>MOD+</sub>), or Advanced (A+T<sub>HIGH+</sub>) stages. Figure 3 (left: CU & CI combined; right: CI  
322 only) displays the logistic regression probability scores for each stage as a function of plasma  
323 p217+tau concentrations. At any given plasma p217+tau value, an individual is most likely to  
324 belong to the stage with the highest probability score. Individuals with low p217+tau  
325 concentrations (below 110 fg/ml for CU & CI combined, or 93 fg/ml for CI only) had the  
326 highest likelihood of being A-T-. A+T<sub>None/MTL</sub> was the classification with the highest  
327 likelihood in p217+tau value range of 110-172 fg/ml for CU & CI combined, and 93-150  
328 fg/ml for CI only. A+T<sub>MOD+</sub> was the most likely classification for a wide range of moderate  
329 p217+tau values (172-375 fg/ml for CU & CI combined, and 150-374 fg/ml for CI only). For  
330 p217+tau values higher than ~375 fg/ml, the classification of A+T<sub>HIGH+</sub> was the most likely.  
331 In Figure 3, the likelihoods from logistic regression (solid line) are compared to the ones  
332 estimated using the sliding window method (dots), indicating good concordance between the  
333 two approaches in computing probabilities.

334

335



336

337 Figure 3. Logistic regression probability scores vs. plasma p217+tau concentration values.  
338 CU & CI combined, on the left. CI only on the right. Line is the probability scores  
339 generated by logistic regression and dots are the probability scores generated by sliding  
340 window methods.  $A-T-$  amyloid negative and tau negative;  $A+T_{None/MTL}$  amyloid positive  
341 and tau negative or amyloid positive with tau uptake limited to medial temporal region;  
342  $A+T_{MOD+}$  amyloid positive with moderate tau uptake in temporo-parietal region;  $A+T_{HIGH+}$   
343 amyloid positive with high tau uptake in temporo-parietal region.



## 344 Discussion

345 In the present study, we evaluated the ability of plasma p217+tau to discriminate between AD  
346 disease stages, employing the biological PET stages recommended by draft NIA-AA Revised  
347 Criteria 2023<sup>9</sup> where we have defined the Advanced stage as >80 Centaur (2.68 SUVR<sub>temporo-</sub>  
348 parietal). We showed that as disease progressed from A-T- to the Advanced biological PET  
349 stages (A+T<sub>HIGH+</sub>), there was a clear incremental trend in plasma p217+tau concentration,  
350 with A+T- or A+T<sub>MTL+</sub> experiencing an almost two-fold increase, A+T<sub>MOD+</sub> more than a  
351 three-fold increase, and A+T<sub>HIGH+</sub> more than a five-fold increase in p217+tau, relative to A-  
352 T-.

353 Next, our group-level analysis was performed with a clinical trial in mind, where establishing  
354 cut-off points allowed screening individuals at certain disease stages in or out of the trial or  
355 enabled grouping enrolled participants for analytical purposes. This is critical as clinical trials  
356 move to recruit participants based on not merely A $\beta$  or tau positive or negative status, but  
357 enroll based on magnitude and topographical distribution of A $\beta$  and tau (such as  
358 TRAILBLAZER-ALZ 2<sup>1</sup>). With high cost and limited availability of PET, predicting level  
359 and spatiotemporal patterns of AD pathology, particularly for tau, using plasma biomarkers  
360 becomes a priority.

361 Group-level examination of how well plasma p-tau217 can distinguish between different  
362 Braak-like PET stages in CU has been reported in a recent study by Jack *et al.*<sup>23</sup>. They found  
363 that p-tau217 discriminated between tau PET negative and tau PET positive (any Braak-like  
364 PET stage) with an AUC of 0.83 which was not significantly different from the  
365 discrimination by Quanterix p-tau181 or a base model including age, sex and *APOE*. Only  
366 37% of our CU were A+, and among these, only a few had high neocortical tau burden, so  
367 our study lacked the statistical power to discriminate between AD biological PET stages  
368 within the CU group. Thus, we chose to limit our report to either the CU & CI combined  
369 group or CI-only group.

370 Here, we showed that if screening for participants with early symptomatic AD, with A $\beta$  and  
371 intermediate/high neocortical tau (similar to TRAILBLAZER-ALZ 2), plasma p217+tau  
372 could discriminate between participants at these stages and other CI participants with an  
373 AUC of 0.89, and if the Youden threshold derived in this cohort for this purpose of 177.4  
374 fg/ml was used, 94% of p217+tau positive participants would be in the target PET stages  
375 (Intermediate/Advanced: A+T<sub>MOD+</sub> or A+T<sub>HIGH+</sub>). However, when investigating the utility of  
376 plasma p217+tau for separating advanced (A+T<sub>HIGH+</sub>) stage of AD in the participants above



377 the p217+tau threshold of 177.4 fg/ml, the AUC was lower (0.75) and the Youden threshold  
378 gave a NPV of 0.84 with a PPV of only 0.51. Tau PET scan would still be essential for  
379 separating A+T<sub>MOD</sub>+ from A+T<sub>HIGH</sub>+.  
380 Alternatively, if a trial were to enrol symptomatic participants but exclude those with  
381 Advanced stage AD (A+T<sub>HIGH</sub>+), we showed that 95% of CI participants with plasma  
382 p217+tau < 230.3 fg/ml were in disease stages lower than A+T<sub>HIGH</sub>+ and therefore this  
383 threshold could be appropriate for exclusion of A+T<sub>HIGH</sub>+.  
384 The pairwise discrimination of each pair of AD biological PET stages —Initial vs. Early,  
385 Early vs. Intermediate, and Intermediate vs. High— yielded lower AUC values. The AUC of  
386 0.64 for Initial vs. Early, suggested that p217+tau did not have adequate discriminatory  
387 performance for these two stages and provided additional support for combining these two  
388 into one stage for subsequent analyses. The AUC of 0.76, observed in the discrimination  
389 between Early and Intermediate stages, falls within an acceptable yet relatively lower range.  
390 This highlights that the higher AUC of 0.92 reported for the A-T-/Initial/Early vs.  
391 Intermediate/Advanced discrimination is predominantly influenced by the inclusion of more  
392 extreme values from A-T- and Advanced stages in the discrimination. The same reasoning  
393 applies to the AUC of 0.77 for Intermediate vs. High relative to the AUC of 0.91 for A-T-  
394 /Initial/Early/Intermediate vs. Advanced.  
395 Previous studies have shown that <sup>18</sup>F-MK6240 might be better suited to detect early tau  
396 accumulation (Me ROI) compared to <sup>18</sup>F-Flortaucipir<sup>24,25</sup>, thus our use of <sup>18</sup>F-MK6240 as  
397 tau PET tracer (as compared to Flortaucipir in the study by Jack *et al.*) may have provided a  
398 more optimal identification of Early stage AD. Yet our findings with <sup>18</sup>F-MK6240 were not  
399 able to show that plasma p217+tau was able to discriminate A+T- from A+T<sub>MTL</sub>+.  
400 In a patient-centric approach, an individual's absolute risk of having AD pathology at a given  
401 plasma biomarker concentration may be more relevant for clinical decision-making.  
402 Therefore, we developed a risk prediction model using p217+tau as the predictor and  
403 estimated probability scores —which are individuals' absolute risk— of falling within a  
404 disease stage for their individual p217+tau level. The plot of the likelihood of PET stage vs.  
405 p217+tau concentration showed good discrimination of A-T- vs any A+ stage and of  
406 combined Intermediate/Advanced disease stage vs lower stages in the CI. However, with the  
407 overlap in likelihood functions for most PET stages, confident staging of an individual with  
408 plasma p217+tau alone is limited. One instead should consider an individual participant's

409 likelihood for belonging to each of the stages based on their p217+tau level as illustrated by  
410 Figure 3.

411 A limitation of this study is that the findings are derived from a research cohort with a  
412 relatively high prevalence of A $\beta$ -PET positivity in the three clinical groups. Replication of  
413 prevalence-dependent findings (i.e., PPV, NPV, estimated probability scores) in a “real-  
414 world” memory clinic setting is needed before any of the findings could be applied in clinical  
415 practice. Moreover, future studies are needed to develop risk prediction models using a  
416 combination of several factors to accurately predict individual-level disease stages.

417 To conclude, plasma p217+tau performs well for group-level discrimination between disease  
418 stages (except Initial and Early), a useful property for clinical trial screening and enrichment.

## 419 Acknowledgments

420 Some data used in this research article were obtained from the Australian Imaging Biomarkers  
421 and Lifestyle flagship study of aging (AIBL), funded by the Commonwealth Scientific and  
422 Industrial Research Organization (CSIRO), National Health and Medical Research Council  
423 (NHMRC), and other participating institutions. Some data were obtained from the Australian  
424 Dementia Network (ADNeT) that receives funding support from the NHMRC. AIBL  
425 researchers are listed on the website [www.aibl.csiro.au](http://www.aibl.csiro.au). The authors thank those who  
426 participated in the study, as well as their families.

## 427 Funding

428 The research was supported by the Australian Federal Government through NHMRC grants  
429 APP1132604, APP1140853 and APP1152623 and by a grant from Enigma Australia. Janssen  
430 Pharmaceuticals paid a commercial data access fee to the AIBL study of ageing. Janssen  
431 Pharmaceuticals performed the p217+tau measurements but did not perform the data analysis.  
432 The co-authors employed by Janssen did provide comments on the manuscript and Janssen  
433 provided approval for submission of the manuscript. The other sponsors had no role in the  
434 design and conduct of the study, in the collection, analysis, and interpretation of data, or in the  
435 preparation of the manuscript.

## 436 Competing interests

437 Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen,  
438 Eisai and Abbvie. He is on the scientific advisory board for Cerveau Technologies and has  
439 consulted for Prothena, Eisai, Roche, and Biogen Australia. Victor L. Villemagne is and has  
440 been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular  
441 Imaging, GE Healthcare, IXICO, Abbvie, Lundbeck, Shanghai Green Valley Pharmaceutical  
442 Co Ltd, AC Immune and Hoffmann La Roche. Ziad S. Saad, Gallen Triana-Baltzer, and  
443 Hartmuth C. Kolb are employees of Janssen Pharmaceuticals. Simon M. Laws is a scientific  
444 advisor for Cytos Ltd. The other authors did not report any conflict of interest.

## 445 References

- 446 1. Sims JR, *et al.* Donanemab in Early Symptomatic Alzheimer Disease: The  
447 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA* **330**, 512-527 (2023).
- 448 2. Janelidze S, *et al.* Head-to-head comparison of 10 plasma phospho-tau assays in  
449 prodromal Alzheimer's disease. *Brain* **146**, 1592-1601 (2023).
- 450 3. Groot C, *et al.* Diagnostic and prognostic performance to detect Alzheimer's disease  
451 and clinical progression of a novel assay for plasma p-tau217. *Alzheimers Res Ther*  
452 **14**, 67 (2022).
- 453 4. Doré V, *et al.* Plasma p217+ tau versus NAV4694 amyloid and MK6240 tau PET  
454 across the Alzheimer's continuum. *Alzheimers Dement: Diagn Assess Dis Monit* **14**,  
455 e12307 (2022).
- 456 5. Feizpour A, *et al.* Two-Year Prognostic Utility of Plasma p217+tau across the  
457 Alzheimer's Continuum. *J Prev Alzheimers Dis* **10**, 828-836 (2023).
- 458 6. Jack CR, *et al.* Predicting amyloid PET and tau PET stages with plasma biomarkers.  
459 *Brain* **146**, 2029-2044 (2023).
- 460 7. Therriault J, *et al.* Biomarker modeling of Alzheimer's disease using PET-based  
461 Braak staging. *Nat Aging* **2**, 526-535 (2022).
- 462 8. Rullmann M, *et al.* Multicenter 18F-PI-2620 PET for in vivo Braak staging of tau  
463 pathology in Alzheimer's disease. *Biomolecules* **12**, 458 (2022).
- 464 9. NIA-AA. NIA-AA Revised Criteria for Alzheimer's Disease - AAIC 2023 DRAFT.  
465 (2023).
- 466 10. Fowler C, *et al.* Fifteen years of the australian imaging, biomarkers and lifestyle  
467 (AIBL) study: progress and observations from 2,359 older adults spanning the  
468 spectrum from cognitive normality to Alzheimer's disease. *J Alzheimers Dis Rep* **5**,  
469 443-468 (2021).
- 470 11. McKhann GM, *et al.* The diagnosis of dementia due to Alzheimer's disease:  
471 recommendations from the National Institute on Aging-Alzheimer's Association  
472 workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**,  
473 263-269 (2011).
- 474 12. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild  
475 cognitive impairment: a concept in evolution. *J Intern Med* **275**, 214-228 (2014).
- 476 13. Bourgeat P, *et al.* Comparison of MR-less PiB SUVR quantification methods.  
477 *Neurobiol Aging* **36**, S159-S166 (2015).
- 478 14. Bourgeat P, *et al.* Implementing the centiloid transformation for 11C-PiB and  $\beta$ -  
479 amyloid 18F-PET tracers using CapAIBL. *Neuroimage* **183**, 387-393 (2018).
- 480 15. Rowe CC, *et al.* Standardized expression of 18F-NAV4694 and 11C-PiB  $\beta$ -amyloid  
481 PET results with the Centiloid scale. *J Nucl Med* **57**, 1233-1237 (2016).
- 482 16. Dore V, *et al.* Ic-P-167: automated reporting of tau PET quantification on brain  
483 surface. *Alzheimers Dement* **15**, P131-P132 (2019).
- 484 17. Villemagne V, Dore V, Bourgeat P. The Tau MeTeR composites for the generation of  
485 continuous and categorical measures of tau deposits in the brain. *J Mol Med Ther* **1**,  
486 25-32 (2017).

487

- 488 18. Doré V, *et al.* Relationship between amyloid and tau levels and its impact on tau  
489 spreading. *Eur J Nucl Med Mol Imaging* **48**, 2225-2232 (2021).
- 490 19. Dore V, *et al.* A CenTauR scale based on 18F-MK6240. *Alzheimer's Association*  
491 *International Conference*, (2023).
- 492 20. Villemagne VL, *et al.* CenTauR: Toward a universal scale and masks for  
493 standardizing tau imaging studies. *Alzheimers Dement: Diagn Assess Dis Monit* **15**,  
494 e12454 (2023).
- 495 21. Triana-Baltzer G, *et al.* Development and validation of a high-sensitivity assay for  
496 measuring p217+ tau in plasma. *Alzheimers Dement: Diagn Assess Dis Monit* **13**,  
497 e12204 (2021).
- 498 22. Krishnadas N, *et al.* Exploring discordant low amyloid beta and high neocortical tau  
499 positron emission tomography cases. *Alzheimers Dement (Amst)* **14**, e12326 (2022).
- 500 23. Jack Jr CR, *et al.* Predicting amyloid PET and tau PET stages with plasma  
501 biomarkers. *Brain* **146**, 2029-2044 (2023).
- 502 24. Bourgeat P, *et al.* Cross-Sectional and Longitudinal Comparison of Tau Imaging with  
503 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and  
504 Brain Beta-Amyloid Burden. *J Prev Alzheimers Dis* **10**, 251-258 (2023).
- 505 25. Gogola A, *et al.* Direct Comparison of the Tau PET Tracers (18)F-Flortaucipir and  
506 (18)F-MK-6240 in Human Subjects. *J Nucl Med* **63**, 108-116 (2022).

507

508